A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone receptor positive (HR+), human epidermal growth factor receptor negative (HER2-) breast cancer.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participant must have a stage IV diagnosis of one of the following: KRAS mt, PD-L1+ NSCLC, squamous NSCLC or HR+, HER2, metastatic breast cancer
Participant must be willing and able to provide tumor tissue both prior to treatment and after treatment initiation
Participant must have discontinued all previous treatments for cancer and recovered from the acute effects of therapy
Participants Must Not:
Participant must not have a history of interstitial lung disease or pneumonitis
Participant must not have a history of or active autoimmune disease, or other syndrome that requires systemic steroids or autoimmune agents for the past 2 years
Participant must not have received a live vaccination within 30 days of study start
Participant must not have received prior treatment with an anti PD-1, anti-programmed death ligand 1 (PD-L1), or anti cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) agent
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo